Navigation Links
Multidisciplinary Association for Psychedelic Studies (MAPS) Selects Montrium's eTMF Platform as They Begin Phase 3 Studies of MDMA-assisted Psychotherapy for PTSD
Date:9/18/2017

MONTREAL, Sept. 18, 2017 /PRNewswire/ -- Montrium, a growing leader in Electronic Trial Master file solutions, today announced an exciting new partnership with a groundbreaking non-profit research organization, Multidisciplinary Association for Psychedelic Studies (MAPS).

MAPS Public Benefit Corporation selects eTMF Connect for MDMA-assisted psychotherapy studies for PTSD
MAPS Public Benefit Corporation selects eTMF Connect for MDMA-assisted psychotherapy studies for PTSD

The FDA has recently granted Breakthrough Therapy Designation to MDMA for the treatment of Posttraumatic Stress Disorder (PTSD). MAPS also reached agreement with the FDA on the design of two Phase 3 clinical trials for MDMA-assisted psychotherapy in patients with severe PTSD through a Special Protocol Assessment (SPA). MAPS has selected Montrium's Electronic Trial Master File solution (eTMF), eTMF Connect, to support these upcoming Phase 3 studies and subsequent clinical trials.

"With such positive results during our Phase 2 trials we were confident that we would receive approval by the FDA to initiate Phase 3 studies on a larger patient population," said Amy Emerson, Director of Clinical Research and Executive Director at MPBC Public Benefit Corporation. "We realized very early on that to scale our Phase 2 successes in the next step of our journey, bringing in the appropriate technology to support this activity would be key. By partnering with Montrium, we not only leverage a sophisticated and robust eTMF system, but a knowledgeable and dedicated partner in the clinical trial arena."

Montrium's eTMF Connect solution will help MAPS improve the efficiency of trial processes by managing documents, data, and clinical activities on a single cloud platform. Researchers and Clinical teams will now be able to access clinical documents and information in real-time significantly improving collaboration and transparency. In addition, MAPS also strengthens the partnership further by joining Montrium's Customer Advisory Program to actively participate in the shaping Montrium's product development roadmap.

"As a small team paving the way in MDMA-assisted psychotherapy, MAPS faces several key challenges as they begin to scale their successes in clinical treatments," said Paul Fenton, President & CEO of Montrium. "We are extremely excited to have been selected to help support the great work the MAPS team is doing as they overcome these challenges and ensure the valuable research they are conducting reaches those in need."

About eTMF Connect

Montrium's proven eTMF Connect solution helps life sciences companies better manage their clinical trial documentation. It has been designed using the TMF Reference Model, and centralizes and standardizes your clinical records enabling both sponsors and CRO's to contribute and access important clinical documents and information in real-time. You can learn more about eTMF Connect by visiting www.montrium.com/etmf-connect

About Montrium:

Montrium is a global leader in cloud-based document & quality management solutions and GxP consulting services for the Life Sciences. Operating in the Life Sciences for over 10 years, Montrium has been successfully helping organizations implement and maintain technology to improve their business processes and increase compliance. Montrium currently serves over 8000 users in more than 20 countries. For more information on the products and services Montrium provides, please visit: www.montrium.com.

About MPBC and MAPS:

Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Since its founding, MAPS has raised over $43.7 million for psychedelic therapy and medical marijuana research and education. For more information, visit MAPS.org.

MAPS-sponsored clinical trials are conducted by the MPBC Public Benefit Corporation (MPBC), a wholly owned subsidiary of MAPS formed in 2015 for the special purpose of balancing social benefits with income from legal sales of MDMA, other psychedelics, and marijuana. For more information, visit MPBCbcorp.com

Media contact:
Oliver Pearce
176260@email4pr.com 
514 223 9153

View original content with multimedia:http://www.prnewswire.com/news-releases/multidisciplinary-association-for-psychedelic-studies-maps-selects-montriums-etmf-platform-as-they-begin-phase-3-studies-of-mdma-assisted-psychotherapy-for-ptsd-300520450.html


'/>"/>
SOURCE Montrium
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. CD-adapco's STAR Academy Accelerates Multidisciplinary Simulation Learning Curve
2. Third Annual Healthcare Leadership Forum Expands to Include Multidisciplinary Evidence-Based Practice Across Healthcare
3. Benchworks President Melissa Johnston Named Treasurer for Healthcare Businesswomen’s Association (HBA) Mid-Atlantic Chapter
4. Inspirata to Participate in Thought Leadership for Cancer Information Sharing at the Association for Pathology Informatics Annual Summit in Pittsburgh May 22-25
5. CNSDose to Demonstrate Leading Genetic Technology for Prescribing Antidepressants at the American Psychiatric Association Annual Meeting
6. Trust Transparency Consulting Launches Ingredient Trade Association Incubator Program
7. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
8. Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
9. Nerium International Approved as Member of the Mexican Direct Selling Association A.C.
10. Pertheras Chief Bioinformatics Officer Speaking at The American Medical Informatics Association (AMIA) 2017 Joint Summits Panels
11. Cellecta, Inc. Announces Upcoming Presentations at the American Association for Cancer Research 2017 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2018)... ... ... The incredible life story of former refugee and LG Sonic CEO Yousef ... the European Commissioner for Research and Innovation. , In his November 27th speech ... spoke at length of Yousef’s life and journey, citing the man who convinced him ...
(Date:11/29/2018)... Utah (PRWEB) , ... November 29, 2018 , ... RAGS, ... was led by Kickstart Seed Fund, with participation from existing investor and board member ... and Davis Smith of Cotopaxi. The additional funding will enable the company to accelerate ...
(Date:11/26/2018)... (PRWEB) , ... November 26, 2018 , ... ... company backed by Siemens Healthineers and Omphalos Venture Partners (Virtual Radiologic founders) among ... Annual Meeting from Nov. 25-29 at McCormick Place in Chicago. The company is ...
(Date:11/20/2018)... ... ... Each year Forbes receives thousands of nominations for candidates wishing to be selected ... 30 years of age. The Forbes 30 Under 30 list showcases the top 30 ... and Science. , In 2017, Visikol CEO Dr. Michael Johnson was named to ...
Breaking Biology Technology:
(Date:11/27/2018)... (PRWEB) , ... November 27, 2018 , ... ... the cryogenics industry a sealing solution with a broader range of usage temperature ... No-1 PEEK expert will introduce its new VICTREX CT™ 200 for dynamic sealing ...
(Date:11/20/2018)... , ... November 19, 2018 , ... ... Applications (academic research tools, drug development, agriculture, human clinical therapeutics, and animal and ... products), by Technology (drug compound and target screening, and agriculture and industrial use), ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... called All Things Chemical™ and it will engage listeners in intelligent, insightful conversation ... business issues surrounding chemicals. B&C’s talented team of lawyers, scientists, and consultants will ...
Breaking Biology News(10 mins):